Hepatitis C pharmacogenetics: State of the art in ... [Hepatology. 2011] - PubMed result

Hepatology. 2011 Jan;53(1):336-345. doi: 10.1002/hep.24052.

Hepatitis C pharmacogenetics: State of the art in 2010.
Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS, Shianna KV, Tanaka Y, Thomas DL, Booth DR, Goldstein DB; for the Pharmacogenetics and Hepatitis C Meeting Participants.

Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA. nafdhal@caregroup.harvard.edu.

Abstract

In 2009, a correlated set of polymorphisms in the region of the interleukin-28B (IL28B) gene were associated with clearance of genotype 1 hepatitis C virus (HCV) in patients treated with pegylated interferon-alfa and ribavirin. The same polymorphisms were subsequently associated with spontaneous clearance of HCV in untreated patients. The link between IL28B genotype and HCV clearance may impact decisions regarding initiation of current therapy, the design and interpretation of clinical studies, the economics of treatment, and the process of regulatory approval for new anti-HCV therapeutic agents. (Hepatology 2011).

Copyright © 2010 American Association for the Study of Liver Diseases.
PMID: 21254181 [PubMed - as supplied by publisher]
Hepatitis C pharmacogenetics: State of the art in ... [Hepatology. 2011] - PubMed result